BACKGROUND: The incidence of non-Hodgkin lymphoma (NHL) in human immunodeficiency virus (HIV)-infected patients remains high despite treatment with antiretroviral therapy (ART). METHODS: We evaluated NHL incidence in HIV-infected patients followed in the Centers for AIDS Research Network of Integrated Clinical Systems who started combination ART and achieved suppression of HIV. We estimated the hazard ratio for NHL by time-varying HIV viremia categories, accounting for time-varying CD4 cell count using marginal structural models. RESULTS: We observed 37 incident NHL diagnoses during 21 607 person-years of follow-up in 6036 patients (incidence rate, 171 per 100 000 person-years; 95% confidence interval [CI], 124-236). NHL incidence was high even among patients with nadir CD4 cell count >200 cells/µL (140 per 100 000 person-years [95% CI, 80-247]). Compared with ≤50 copies/mL, hazard ratios (HRs) for NHL were higher among those with HIV viremia of 51-500 copies/mL (HR current = 1.66 [95% CI, .70-3.94]; HR 3-month lagged = 2.10 [95% CI, .84-5.22]; and HR 6-month lagged = 1.46 [95% CI, .60-3.60]) and >500 copies/mL (HR current = 2.39 [95% CI, .92-6.21]; HR 3-month lagged = 3.56 [95% CI, 1.21-10.49]; and HR 6-month lagged = 2.50 [95% CI, .91-6.84]). Current HIV RNA as a continuous variable was also associated with NHL (HR = 1.42 per log10 copies/mL [95% CI, 1.05-1.92]). CONCLUSIONS: Our findings demonstrate a high incidence of NHL among HIV-infected patients on ART and suggest a role of HIV viremia in the pathogenesis of NHL. Earlier initiation of potent ART and maximal continuous suppression of HIV viremia may further reduce NHL risk.
BACKGROUND: The incidence of non-Hodgkin lymphoma (NHL) in human immunodeficiency virus (HIV)-infectedpatients remains high despite treatment with antiretroviral therapy (ART). METHODS: We evaluated NHL incidence in HIV-infectedpatients followed in the Centers for AIDS Research Network of Integrated Clinical Systems who started combination ART and achieved suppression of HIV. We estimated the hazard ratio for NHL by time-varying HIV viremia categories, accounting for time-varying CD4 cell count using marginal structural models. RESULTS: We observed 37 incident NHL diagnoses during 21 607 person-years of follow-up in 6036 patients (incidence rate, 171 per 100 000 person-years; 95% confidence interval [CI], 124-236). NHL incidence was high even among patients with nadir CD4 cell count >200 cells/µL (140 per 100 000 person-years [95% CI, 80-247]). Compared with ≤50 copies/mL, hazard ratios (HRs) for NHL were higher among those with HIV viremia of 51-500 copies/mL (HR current = 1.66 [95% CI, .70-3.94]; HR 3-month lagged = 2.10 [95% CI, .84-5.22]; and HR 6-month lagged = 1.46 [95% CI, .60-3.60]) and >500 copies/mL (HR current = 2.39 [95% CI, .92-6.21]; HR 3-month lagged = 3.56 [95% CI, 1.21-10.49]; and HR 6-month lagged = 2.50 [95% CI, .91-6.84]). Current HIV RNA as a continuous variable was also associated with NHL (HR = 1.42 per log10 copies/mL [95% CI, 1.05-1.92]). CONCLUSIONS: Our findings demonstrate a high incidence of NHL among HIV-infectedpatients on ART and suggest a role of HIV viremia in the pathogenesis of NHL. Earlier initiation of potent ART and maximal continuous suppression of HIV viremia may further reduce NHL risk.
Authors: Shuangjie Zhang; Ard van Sighem; Anouk Kesselring; Luuk Gras; Colette Smit; Jan M Prins; Robert Kauffmann; Clemens Richter; Frank de Wolf; Peter Reiss Journal: J Acquir Immune Defic Syndr Date: 2012-07-01 Impact factor: 3.731
Authors: M Leruez-Ville; R Seng; P Morand; F Boufassa; F Boue; C Deveau; C Rouzioux; C Goujard; J M Seigneurin; L Meyer Journal: HIV Med Date: 2012-03-14 Impact factor: 3.180
Authors: Marta Epeldegui; Dharma R Thapa; Justin De la Cruz; Scott Kitchen; Jerome A Zack; Otoniel Martínez-Maza Journal: PLoS One Date: 2010-07-06 Impact factor: 3.240
Authors: Meredith S Shiels; Eric A Engels; Martha S Linet; Christina A Clarke; Jianmin Li; H Irene Hall; Patricia Hartge; Lindsay M Morton Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-04-17 Impact factor: 4.254
Authors: Michael J Silverberg; Chun Chao; Wendy A Leyden; Lanfang Xu; Beth Tang; Michael A Horberg; Daniel Klein; Charles P Quesenberry; William J Towner; Donald I Abrams Journal: AIDS Date: 2009-11-13 Impact factor: 4.177
Authors: Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: David J Riedel; Kristen A Stafford; Aparna Vadlamani; Robert R Redfield Journal: AIDS Res Hum Retroviruses Date: 2016-12-13 Impact factor: 2.205
Authors: Jennifer S Lee; Stephen R Cole; David B Richardson; Dirk P Dittmer; William C Miller; Richard D Moore; Mari Kitahata; Christopher Mathews; Kenneth Mayer; Elvin Geng; Chad J Achenbach; Joseph J Eron Journal: AIDS Date: 2017-09-10 Impact factor: 4.177
Authors: Leah Shepherd; Lene Ryom; Matthew Law; Camilla Ingrid Hatleberg; Stephane de Wit; Antonella d'Arminio Monforte; Manuel Battegay; Andrew Phillips; Fabrice Bonnet; Peter Reiss; Christian Pradier; Andrew Grulich; Caroline Sabin; Jens Lundgren; Amanda Mocroft Journal: J Natl Cancer Inst Date: 2018-06-01 Impact factor: 13.506
Authors: Nikolas I Wada; Jay H Bream; Otoniel Martínez-Maza; Bernard Macatangay; Shannon R Galvin; Joseph B Margolick; Lisa P Jacobson Journal: Clin Infect Dis Date: 2016-06-25 Impact factor: 9.079
Authors: Elizabeth L Yanik; Chad J Achenbach; Satish Gopal; Anna E Coghill; Stephen R Cole; Joseph J Eron; Richard D Moore; W Christopher Mathews; Daniel R Drozd; Ayad Hamdan; Mary E Ballestas; Eric A Engels Journal: J Clin Oncol Date: 2016-08-09 Impact factor: 44.544